In company news, PureTech Health reported US Food & Drug Administration approval for its schizophrenia drug, and abrdn Property Income Trust agreed to sell a subsidiary for GBP351 million. Here is ...

This approval triggers 2 milestone payments totaling $29 million, as per agreements with Royalty Pharma and PureTech's founded entity, Karuna Therapeutics, which was acquired by Bristol Myers Squibb ...

These are the most popular stories from the Wall Street Journal. These stories have not been verified and we cannot vouch their accuracy. U.S.

Bristol Myers Squibb (BMY) announced that the U.S. Food and Drug Administration has approved COBENFY (xanomeline and trospium ...

The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.

The Food and Drug Administration, as expected, approved KarXT, the first new type of drug for schizophrenia in decades. It appears to be effective, but its main advantage is milder side effects.

Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...

The U.S. Food and Drug Administration has granted approval to Cobenfy, the first new schizophrenia drug in decades.

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

This drug takes the first new approach to schizophrenia treatment in decades," Farchione continued. "This approval offers a ...

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.